FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC By Ogkologos - August 5, 2026 9 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ASCENT-03 and ASCENT-04/KEYNOTE D-19 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength Could Functional Precision Medicine Be the New Precision Oncology? Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL MOST POPULAR Opportunity and mentorship: Our new PhD programme aiming to open-up academia... July 22, 2022 Efficacy and Safety of Adding Antiangiogenesis Therapy to First-Line Immunochemotherapy in... August 8, 2024 No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia July 30, 2021 2023 ASCO Annual Meeting Research Round Up: New Research in Treating... September 28, 2023 Load more HOT NEWS Oral Cancer Taught Me How Much Words Matter EMA Recommends Extension of Therapeutic Indications for Pembrolizumab 3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout Cancer waiting times: Latest updates and analysis
